Literature DB >> 12667916

NK1 receptor-mediated mechanisms regulate colonic hypersensitivity in the guinea pig.

Beverley Greenwood-Van Meerveld1, Matthew S Gibson, Anthony C Johnson, Kalina Venkova, Debra Sutkowski-Markmann.   

Abstract

Neurokinin-1 (NK(1)) receptors activated by substance P (SP) are involved in the processing of nociceptive information and are a potential target for therapy of visceral pain. We have evaluated the role of NK(1) receptors using a selective antagonist of NK(1) receptors in two animal models of colorectal hypersensitivity. The behavioral response to colorectal distension was assessed in freely moving guinea pigs by recording visceromotor reflex contractions of the abdominal musculature. Colonic hypersensitivity was induced by intracolonic administration of a chemical irritant (0.6% of acetic acid), or by acute partial restraint stress. Sensitization was characterized by an exaggerated visceromotor response to a low level of colorectal distension (10 mm Hg). In both models of colonic hypersensitivity, oral administration of TAK-637 (0.1-10 mg/kg) normalized visceromotor responses. The intracerebroventricular (10 microg/kg) or intrathecal (10 microg/kg) administration of TAK-637 inhibited colonic hypersensitivity, suggesting an interaction with central NK(1) receptors. In contrast, TAK-637 had no effect on visceromotor responses to colorectal distension at 40 mm Hg in guinea pigs with normosensitive (nonsensitized) colons. In conclusion, central NK(1) receptors play a significant role in colonic hypersensitivity induced by visceral afferent nerve sensitization from gastrointestinal origin or acute psychosomatic stress, but not in the perception of colorectal distension in animals with normosensitive colons.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667916     DOI: 10.1016/s0091-3057(03)00032-7

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  9 in total

Review 1.  Psychological stress in IBD: new insights into pathogenic and therapeutic implications.

Authors:  J E Mawdsley; D S Rampton
Journal:  Gut       Date:  2005-10       Impact factor: 23.059

Review 2.  Stress and visceral pain: from animal models to clinical therapies.

Authors:  Muriel Larauche; Agata Mulak; Yvette Taché
Journal:  Exp Neurol       Date:  2011-05-06       Impact factor: 5.330

Review 3.  Novel therapeutic approaches in IBS.

Authors:  Sylvie Bradesi; Emeran A Mayer
Journal:  Curr Opin Pharmacol       Date:  2007-11-19       Impact factor: 5.547

Review 4.  Visceral pain: the neurophysiological mechanism.

Authors:  Jyoti N Sengupta
Journal:  Handb Exp Pharmacol       Date:  2009

Review 5.  Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.

Authors:  Gareth J Sanger
Journal:  Br J Pharmacol       Date:  2004-03-15       Impact factor: 8.739

6.  Involvement of substance P in the development of cisplatin-induced acute and delayed pica in rats.

Authors:  Kouichi Yamamoto; Keiko Asano; Ayana Tasaka; Yuko Ogura; Seikou Kim; Yui Ito; Atsushi Yamatodani
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

7.  Comparison of NK-1 Receptor Antagonist (Maropitant) to Morphine as a Pre-Anaesthetic Agent for Canine Ovariohysterectomy.

Authors:  Megan Marquez; Pedro Boscan; Heather Weir; Pamela Vogel; David C Twedt
Journal:  PLoS One       Date:  2015-10-29       Impact factor: 3.240

8.  Acute colitis induces neurokinin 1 receptor internalization in the rat lumbosacral spinal cord.

Authors:  Ming-Ming Zhang; Wei Ji; Li-Yu Pei; Wen Wang; Tao Chen; Wei Wang; Hui Li; Ting Zhang; Sheng-Xi Wu; Yun-Qing Li
Journal:  PLoS One       Date:  2013-03-21       Impact factor: 3.240

9.  Morphine Perinatal Exposure Induces Long-Lasting Negative Emotional States in Adult Offspring Rodents.

Authors:  Nair C F Castro; Izabelle S Silva; Sabrina C Cartágenes; Luanna M P Fernandes; Paula C Ribera; Mayara A Barros; Rui D Prediger; Enéas A Fontes-Júnior; Cristiane S F Maia
Journal:  Pharmaceutics       Date:  2021-12-24       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.